The partnership is anchored by shared investment, a resilient dual supply chain and a deliberate focus on cost leadership, positioning both companies to serve the accessible type 2 diabetes and obesity care market at scale as reference exclusivities expire. It is underpinned by a recent first regulatory milestone: the U.S. Food and Drug Administration (FDA) has accepted for review two Abbreviated New Drug Applications (ANDAs) for generic tirzepatide injection in the United States, both filed at NCE-1.
Tirzepatide has rapidly become one of the most important therapies in metabolic disease, reflecting strong growth across both diabetes and obesity care worldwide. Through their expanded collaboration, Adalvo and Richter are positioning themselves to support broader access to high-quality treatment options while building a long-term platform in one of healthcare's fastest-growing markets.
The tirzepatide franchise, comprising Mounjaro and Zepbound, reached combined 2025 sales of around USD 36.5 billion1, according to company reports, more than double the prior year, highlighting the scale and momentum behind the molecule.
Head of General Medicines at Gedeon Richter, Bence Kovács commented: “Building on our Wegovy collaboration, we are pleased to be joining forces with Adalvo on tirzepatide to expand global patient access in this fast growing therapeutic field. Our companies are different by design, and that diversity, combined with deep mutual respect, is what makes this partnership so powerful.”
Adalvo's CEO, Anil Okay, commented: "Adalvo and Gedeon Richter are building for the next era of accessible diabetes and obesity care. This is a partnership of equals: shared investment, shared values, and a supply model built for resilience and genuine cost leadership. By moving early and putting the right foundations in place, we are positioning to bring these therapies to patients on a global scale as the market opens up."
The expanded partnership positions Adalvo and Richter as first movers in accessible diabetes and obesity care, reflecting a long-term strategy: scientifically rigorous, global in reach, resilient in supply, and anchored in a partnership of the highest order.
- Source: Eli Lilly and Company, Annual Report on Form 10-K for the year ended 31 December 2025. Combined figure reflects reported Mounjaro and Zepbound net revenues
About Richter
Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives breakthroughs in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com
About Adalvo
Adalvo is a leading global B2B pharmaceutical company, combining a differentiated portfolio with an end-to-end platform that brings complex generics, 505(b)(2) products, peptides, biosimilars and GLP-1s to market quickly and sustains reliable supply over the long term. From portfolio selection through development, regulatory and supply to commercial out-licensing, Adalvo partners with over 170 pharmaceutical companies across more than 140 countries, turning technical capability into repeatable, first-to-market delivery. Headquartered in Switzerland and backed by EQT, Adalvo is committed to making a difference for patients around the world. First to market, built to last.
Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Wegovy is a registered trademark of Novo Nordisk A/S.
For further information:
Richter
Investors: Róbert Réthy, CFA +36 20 342 2555
Media: Zsuzsa Beke +36 20 916 4507
Adalvo
Media: Annabelle Harrison +44 770 770 3483